Approval Year
Substance Class |
Protein
Created
by
admin
on
Edited
Mon Mar 31 21:57:14 GMT 2025
by
admin
on
Mon Mar 31 21:57:14 GMT 2025
|
Protein Sub Type | |
Sequence Type | COMPLETE |
Record UNII |
6NP3XSMIP3
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
UCSF-FDA TRANSPORTAL |
SLC47A1
Created by
admin on Mon Mar 31 21:57:14 GMT 2025 , Edited by admin on Mon Mar 31 21:57:14 GMT 2025
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
6NP3XSMIP3
Created by
admin on Mon Mar 31 21:57:14 GMT 2025 , Edited by admin on Mon Mar 31 21:57:14 GMT 2025
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
INHIBITOR -> TRANSPORTER |
IC50
|
||
|
INHIBITOR -> TRANSPORTER | |||
|
SUBSTRATE -> TRANSPORTER | |||
|
INHIBITOR -> TRANSPORTER |
Rifamycin is an inhibitor of renal transporters organic anion transporter (OAT) 3, multidrug and toxin extrusion (MATE) 1, and MATE2-K transporters in vitro, however, based on systemic concentrations of rifamycin observed after administration of the recommended dose, clinically relevant inhibition of these transporters in vivo is unlikely.
|
||
|
INHIBITOR -> TRANSPORTER | |||
|
TRANSPORTER -> INHIBITOR | |||
|
SUBSTRATE -> TRANSPORTER | |||
|
INHIBITOR -> TRANSPORTER | |||
|
INHIBITOR -> TRANSPORTER | |||
|
INHIBITOR -> TRANSPORTER | |||
|
SUBSTRATE -> TRANSPORTER |
|
||
|
INHIBITOR -> TRANSPORTER | |||
|
INHIBITOR -> TRANSPORTER |
IC50
|
||
|
INHIBITOR -> TRANSPORTER | |||
|
SUBSTRATE -> TRANSPORTER | |||
|
SUBSTRATE -> TRANSPORTER | |||
|
SUBSTRATE -> TRANSPORTER | |||
|
INHIBITOR -> TRANSPORTER |
|
||
|
INHIBITOR -> TRANSPORTER | |||
|
INHIBITOR -> TRANSPORTER | |||
|
SUBSTRATE -> METABOLIC ENZYME | |||
|
INHIBITOR -> TRANSPORTER |
IC50
|
||
|
INHIBITOR -> TRANSPORTER | |||
|
INHIBITOR -> TRANSPORTER | |||
|
SUBSTRATE -> TRANSPORTER | |||
|
INHIBITOR -> METABOLIC ENZYME | |||
|
INHIBITOR -> TRANSPORTER | |||
|
INHIBITOR -> TRANSPORTER | |||
|
INHIBITOR -> TRANSPORTER | |||
|
INHIBITOR -> TRANSPORTER |
IC50
|
||
|
SUBSTRATE -> TRANSPORTER |
|
||
|
INHIBITOR -> TRANSPORTER |
IN VITRO
|
||
|
INHIBITOR -> TRANSPORTER | |||
|
INHIBITOR -> TRANSPORTER | |||
|
INHIBITOR -> TRANSPORTER | |||
|
INHIBITOR -> TRANSPORTER | |||
|
INHIBITOR -> TRANSPORTER | |||
|
INHIBITOR -> TRANSPORTER | |||
|
INHIBITOR -> TRANSPORTER | |||
|
INHIBITOR -> TRANSPORTER | |||
|
INHIBITOR -> TRANSPORTER | |||
|
INHIBITOR -> TRANSPORTER | |||
|
INHIBITOR -> TRANSPORTER |
REVERSIBLE
|
||
|
INHIBITOR -> TRANSPORTER | |||
|
INHIBITOR -> TRANSPORTER | |||
|
SUBSTRATE -> TRANSPORTER | |||
|
INHIBITOR -> TRANSPORTER | |||
|
TISSUE EXPRESSION->TRANSPORTER | |||
|
INHIBITOR -> TRANSPORTER |
WEAK
IC50
|
||
|
INHIBITOR -> TRANSPORTER | |||
|
SUBSTRATE -> TRANSPORTER | |||
|
INHIBITOR -> TRANSPORTER | |||
|
INHIBITOR -> TRANSPORTER | |||
|
SUBSTRATE -> TRANSPORTER | |||
|
INHIBITOR -> TRANSPORTER |
The results suggest that KLISYRI has no clinically meaningful effect on the PK of drugs mediated by MATE1
IC50
|
||
|
INHIBITOR -> TRANSPORTER |
IC50
|
||
|
INHIBITOR -> TRANSPORTER | |||
|
INHIBITOR -> TRANSPORTER | |||
|
INHIBITOR -> TRANSPORTER |
corrected for non-specific binding
IC50
|
||
|
SUBSTRATE -> TRANSPORTER | |||
|
SUBSTRATE -> TRANSPORTER | |||
|
SUBSTRATE -> TRANSPORTER | |||
|
INHIBITOR -> TRANSPORTER | |||
|
SUBSTRATE -> TRANSPORTER | |||
|
INHIBITOR -> TRANSPORTER |
Co?administration of BIKTARVY with dofetilide may increase dofetilide plasma concentrations which can lead to serious and/or life threatening events.
CLINICALLY SIGNIFICANT
IC50
|
||
|
INHIBITOR -> TRANSPORTER | |||
|
INHIBITOR -> TRANSPORTER |
IC50
|
||
|
INHIBITOR -> TRANSPORTER | |||
|
SUBSTRATE -> TRANSPORTER |
|
||
|
INHIBITOR -> TRANSPORTER | |||
|
INHIBITOR -> TRANSPORTER |
Structural Modifications
Modification Type | Location Site | Location Type | Residue Modified | Extent | Fragment Name | Fragment Approval |
---|---|---|---|---|---|---|
AMINO_ACID_SUBSTITUTION | [1_1] | M | N-ACETYLMETHIONINE | 9J12WX5B6A |
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
MOL_WEIGHT:NUMBER(CALCULATED) | CHEMICAL |
|